General
Preferred name
INDORAMIN
Synonyms
Wy 2190 ()
Indoramin D5 ()
Indoramine D5 ()
Wy-21901 D5 ()
INDORAMINE ()
Indoramin hydrochloride ()
Wy 21901 ()
Doralese Tiltab ()
Baratol ()
WY-21901 ()
WY-21,901 HCL ()
Indoramin hcl ()
P&D ID
PD009083
CAS
26844-12-2
33124-53-7
38821-52-2
Tags
available
drug candidate
drug
First approval
1981
Drug Status
approved
withdrawn
Drug indication
Hypertension
Antihypertensive
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Indoramin is a selective antagonist of α1-adrenoceptors .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
17
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Guide to Pharmacology
Ki Database
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
ReFrame library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
347.2
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
3.6
TPSA
48.13
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C
Pathway
GPCR/G protein
Neuronal Signaling
Member status
virtual
MOA
alpha1-Adrenoceptor Antagonists
Adrenergic Receptor antagonist
Indication
benign prostatic hyperplasia (BPH), hypertension
Disease Area
urology, cardiology
ATC
C02CA02
Toxicity type
cardiovascular
Source data
